Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening

yf_tkr_WAT · 2026-10-23 · Bullish AI sentiment

$DGX $WAT

Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay. The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening. The Onclarity Self-Collection Kit...

Sector coverage: Healthcare · Diagnostics & Research

Read the original at yf_tkr_WAT ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.